Physicians' Academy for Cardiovascular Education
Using data from the MESA study, it was demonstrated that individuals with irregular sleep duration and timing have increased risk of CVD.
Learn more about PACE-CME, our mission, our programmes and our cardiovascular educational services and resources
A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.
Phase 3 study data with bempedoic acid show 28% additional LDL-c lowering on background therapy and 33% reduction of hsCRP in patients with atherosclerotic CVD or at high risk for ASCVD.
A preclinical study shows that DS-9001a interferes with PCSK9 binding to the LDL receptor and PCSK9-mediated LDLR degradation, and lowers LDL-c, and it is produced in a microbial production system.
12-Week treatment with GPR119 agonist DS-8500a lowers HbA1c, FPG and 2hPPG as compared with placebo, albeit to a lesser extend than sitagliptin, but it also lowered total cholesterol, LDL-c and TG.
Genetic and therapeutic antagonism of angiopoietin-3 in humans and mice improved lipid profiles and lowered CV risk, and oligonucleotide-based inhibition of Angptl3 in mice slowed atheroprogression.
Evinacumab is directed against angiopoietin-like protein 3, which acts as an inhibitor of lipoprotein lipase and endothelial lipase. Positive interim phase 2 results with evinacumab have been reported in HoFH.
Baroreflex activation therapy lowers BP in the long-term, in treatment-resistant hypertensive patients, particularly in those with HF and preserved ejection fraction.
ACC 2017 No difference in cognitive function was seen between evolocumab and placebo-treated patients in the EBBINGHAUS trial. No cognitive decline was seen over time in either treatment group.
ACC 2017 Inclisiran, which prevents PCSK9 protein production, resulted in long-term LDL-c lowering after two doses of siRNA, without safety concerns, in the ORION-1 study.
ACC 2017 Marc S. Sabatine (Boston) presented the FOURIER-study, which evaluated a PCSK9 inhibitor during two years in over 27000 high-risk patients. LDL-c was reduced by 59%. Both the primary and the secundary clinical endpoint were significantly reduced.
